FDA Proposes New Restrictions on Compounded GLP-1 Weight-Loss Drugs

The U.S. Food and Drug Administration (FDA) is proposing significant changes to the regulation of compounded GLP-1 receptor agonists used for weight loss. The agency intends to remove semaglutide, tirzepatide, and liraglutide from the list of drugs eligible for compounding under the 503B category. This action is based on the FDA's determination that legitimate shortages of these popular weight-loss medications from manufacturers like Novo Nordisk and Eli Lilly no longer exist. The FDA's goal is to regain control over the supply chain and uphold the integrity of these widely sought-after treatments. This regulatory shift is expected to impact the pharmaceutical and compounding pharmacy industries, which have been serving high demand due to supply constraints. The agency's move aims to ensure that patients have access to safe and effective treatments while addressing the evolving market dynamics of these blockbuster drugs.